This article was originally published in Pharmaceutical Approvals Monthly
FDA staff that participated in the review of AstraZeneca’s anticoagulant.
You may also be interested in...
Shades Of Prasugrel: Brilinta Review Felt The Effects Of Effient’s Experience
FDA’s review of AstraZeneca’s platelet inhibitor ticagrelor was tinged by the agency’s earlier evaluation and delayed approval of Lilly/Daiichi’s prasugrel for acute coronary syndromes.
Multiple Aspirin Dose Analyses Reassured FDA On Brilinta’s U.S. Efficacy
The consistency of numerous analyses supporting a negative interaction between ticagrelor and high-dose aspirin, as used in the U.S., helped overcome FDA’s initial reluctance to approve AstraZeneca’s platelet inhibitor without a new trial.
Brilinta Review Sparks War Of Words Between FDA Cardio-Renal Division’s Marciniak, Stockbridge
The ticagrelor NDA ignited strong opinions from the cross-discipline team leader about sponsor AstraZeneca’s conduct, drawing a forceful response from the review division director.